Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection

AIDS

Volumn 17, Issue 5, 2003, Pages 645-652

  Brussel, Audrey ^a   Mathez, Dominique ^b   Broche Pierre, Sophie ^a   Lancar, Rémi ^c   Calvez, Thierry ^c   Sonigo, Pierre ^a   Leibowitch, Jacques ^b  

^a INSTITUT COCHIN   (France)

^b Centre d'Immuno Virologie   (France)

^c INSERM   (France)

Author keywords

2 LTR circles; Antiretroviral therapy; HIV 1 DNA; Residual replication

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA;

ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; LONGITUDINAL STUDY; PATIENT MONITORING; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; TREATMENT WITHDRAWAL; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DNA, VIRAL; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; PROVIRUSES; VIREMIA; VIRUS REPLICATION;

EID: 0242499964     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200303280-00001     Document Type: Article

References (30)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
3. Davey RT Jr, Bhat N, Yoder C, Chun T-W, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999, 96:15109-15114.
4. Garcia F, Plana M, Vidal C, Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999, 13:F79-F86.
5. Garcia F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001, 15:F29-F40.
6. Ho DD, Zhang L. HIV-1 rebound after anti-retroviral therapy. Nature Med 2000, 6:736-737.
7. Neumann AU, Tubiana R, Calvez V, Robert C, Li TS, Agut H, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 1999, 13:677-683.
8. Ruiz L, Martinez-Picado J, Romeu J, Ferrer E, Negredo E, Tural C, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000, 14:397-403.
9. Gunthard HF, Frost SD, Leigh-Brown AJ, Ignacio CC, Kee K, Perelson AS, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999, 73:9404-9412.
10. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L Jr, Ingerman M, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999, 282:1627-1632.
11. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999, 340:1614-1622.
12. Orenstein JM, Feinberg M, Yoder C, Schrager L, Mican JM, Schwartzentruber DJ, et al. Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient. AIDS 1999, 13:2219-2229.
13. Natarajan V, Bosche M, Metcalf JA, Ward DJ, Lane HC, Kovacs JA. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet 1999, 353:119-120.
14. Pauza CD, Trivedi P, McKechnie TS, Richman DD, Graziano FM. 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. Virology 1994, 205:470-478.
15. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nature Med 2000, 6:76-81.
16. Burgard M, Izopet J, Dumon B, Tamalet C, Descamps D, Ruffault A, et al. HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment. AIDS Res Hum Retroviruses 2000, 16:1939-1947.
17. Mathez D, Schinazi RF, Liotta DC, Leibowitch J. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob Agents Chemother 1993, 37:2206-2211.
18. Cara A, Vargas J, Jr, Keller M, Jones S, Mosoian A, Gurtman A, et al. Circular viral DNA and anomalous junction in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. Virology 2002, 292:1-5.
19. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
20. Wong JK, Gunthard HF, Havlir DV, Zhang ZQ, Haase AT, Ignacio CC, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997, 94:12574-12579.
21. Bagnarelli P, Mathez D, Paul D, Katlama C, de Truchis P, Valenza A, et al. Dynamics and compartmentalization of HIV-1 biotypes in vivo. Cell Pharmacol-AIDS Sci 1996, 3:81-90.
22. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
23. Debiaggi M, Zara F, Pistorio A, Bruno R, Sacchi P, Patruno SF, et al. Quantification of HIV-1 proviral DNA in patients with undetectable plasma viremia over long-term highly active antiretroviral therapy. Int J Infect Dis 2000, 4:187-193.
24. Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, Harzic M, et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001, 15:665-673.
25. Donovan RM, Bush CE, Smereck SM, Moore E, Cohen F, Saravolatz LD. Antiretroviral therapy is associated with a decrease in unintegrated HIV-1 DNA in pediatric patients. J Acquir Immune Defic Syndr 1994, 7:1237-1241.
26. Ibanez A, Puig T, Elias J, Clotet B, Ruiz L, Martinez MA. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999, 13:1045-1049.
27. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997, 94:13193-13197.
28. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Med 1998, 4:208-214.
29. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. Intrinsic Stability of Episomal Circles Formed during Human Immunodeficiency Virus Type 1 Replication. J Virol 2002, 76:4138-4144.
30. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002, 76:3739-3747.